Heterogeneous Crystallization as a Process Intensification Technology in an Integrated Continuous Manufacturing Process for Pharmaceuticals

被引:23
作者
Testa, Christopher J. [1 ]
Shvedova, Khrystyna [1 ]
Hu, Chuntian [1 ]
Wu, Wei [1 ]
Born, Stephen C. [1 ]
Takizawa, Bayan [1 ]
Mascia, Salvatore [1 ]
机构
[1] CONTINUUS Pharmaceut, Woburn, MA 01801 USA
基金
美国国家科学基金会;
关键词
pharmaceutical production; integrated continuous manufacturing (ICM); process intensification technology (PIT); heterogeneous crystallization; mixed-suspension mixed-product removal (MSMPR) crystallization;
D O I
10.1021/acs.oprd.0c00468
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Continuous heterogeneous crystallization processes in mixed-suspension mixed-product removal (MSMPR) crystallizers of different configurations (e.g., single-stage cooling, multistage cooling, and multistage evaporative cooling) are developed, in which an active pharmaceutical ingredient (acetaminophen, APAP) is crystallized directly on the surfaces of both porous and nonporous polymer excipient substrates (poly(vinyl alcohol), PVA). The heterogeneous crystallization step is part of an integrated continuous manufacturing (ICM) processing train, which starts from raw materials and includes chemical synthesis, crystallization, filtration, and drying. The product from this ICM process is a stream of dried composite particles (i.e., APAP on PVA substrates) that are directly compressed into tablets, eliminating the need for any further processing steps (e.g., milling, sieving, blending, and granulation). The dried composite particles are characterized with scanning electron microscopy, differential scanning calorimetry, and X-ray powder diffraction. The use of porous polymer substrates (instead of nonporous substrates) increased the crystallization yield by >4X in one set of experiments. In subsequent experiments, the use of porous polymer substrates reduced the risk of bulk nucleation (due to increased internal free volume and surface area) in an evaporative-cooling MSMPR crystallization system. Yields as high as 71% and drug loadings as high as 61.1 +/- 2.8% were observed with this evaporative-cooling MSMPR system. Furthermore, it is shown that by altering the suspension density of the excipient particles, the drug loading of the composite particles can be controlled. Finally, the design of the ICM process is discussed. The use of heterogeneous crystallization as a process intensification technology (e.g., incorporation into an end-to-end ICM pharmaceutical production process) has the potential to reduce overall system complexity, capital investment, and operating costs on the commercial scale by reducing the number of downstream processing steps that are required.
引用
收藏
页码:225 / 238
页数:14
相关论文
共 55 条
[1]   Application of Process Analytical Technology-Based Feedback Control for the Crystallization of Pharmaceuticals in Porous Media [J].
Acevedo, David A. ;
Ling, Jing ;
Chadwick, Keith ;
Nagy, Zoltak K. .
CRYSTAL GROWTH & DESIGN, 2016, 16 (08) :4263-4271
[2]   Regulatory and Quality Considerations for Continuous Manufacturing May 20-21, 2014 Continuous Manufacturing Symposium [J].
Allison, Gretchen ;
Cain, Yanxi Tan ;
Cooney, Charles ;
Garcia, Tom ;
Bizjak, Tara Gooen ;
Holte, Oyvind ;
Jagota, Nirdosh ;
Komas, Bekki ;
Korakianiti, Evdokia ;
Kourti, Dora ;
Madurawe, Rapti ;
Morefield, Elaine ;
Montgomery, Frank ;
Nasr, Moheb ;
Randolph, William ;
Robert, Jean-Louis ;
Rudd, Dave ;
Zezza, Diane .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (03) :803-812
[3]   Crystallization of Cyclosporine in a Multistage Continuous MSMPR Crystallizer [J].
Alvarez, Alejandro J. ;
Singh, Aniruddh ;
Myerson, Allan S. .
CRYSTAL GROWTH & DESIGN, 2011, 11 (10) :4392-4400
[4]   Continuous Plug Flow Crystallization of Pharmaceutical Compounds [J].
Alvarez, Alejandro J. ;
Myerson, Allan S. .
CRYSTAL GROWTH & DESIGN, 2010, 10 (05) :2219-2228
[5]   Achieving Continuous Manufacturing: Technologies and Approaches for Synthesis, Workup, and Isolation of Drug Substance May 20-21, 2014 Continuous Manufacturing Symposium [J].
Baxendale, Ian R. ;
Braatz, Richard D. ;
Hodnett, Benjamin K. ;
Jensen, Klavs F. ;
Johnson, Martin D. ;
Sharratt, Paul ;
Sherlock, Jon-Paul ;
Florence, Alastair J. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (03) :781-791
[6]   Influence of Crystallization Conditions on Crystal Morphology and Size of CaCO3 and Their Effect on Pressure Filtration [J].
Beck, Ralf ;
Andreassen, Jens-Petter .
AICHE JOURNAL, 2012, 58 (01) :107-121
[7]   Achieving Continuous Manufacturing for Final Dosage Formation: Challenges and How to Meet Them May 20-21, 2014 Continuous Manufacturing Symposium [J].
Byrn, Stephen ;
Futran, Maricio ;
Thomas, Hayden ;
Jayjock, Eric ;
Maron, Nicola ;
Meyer, Robert F. ;
Myerson, Allan S. ;
Thien, Michael P. ;
Trout, Bernhardt L. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 104 (03) :792-802
[8]   Insight Into a Novel Strategy for the Design of Tablet Formulations Intended for Direct Compression [J].
Capece, Maxx ;
Huang, Zhonghui ;
Dave, Rajesh .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (06) :1608-1617
[9]   Toward the Rational Design of Crystalline Surfaces for Heteroepitaxy: Role of Molecular Functionality [J].
Chadwick, Keith ;
Chen, Jie ;
Myerson, Allan S. ;
Trout, Bernhardt L. .
CRYSTAL GROWTH & DESIGN, 2012, 12 (03) :1159-1166
[10]   Polymorphic control by heterogeneous nucleation - A new method for selecting crystalline substrates [J].
Chadwick, Keith ;
Myerson, Allan ;
Trout, Bernhardt .
CRYSTENGCOMM, 2011, 13 (22) :6625-6627